Avidity Biosciences, Inc Cash Flow-to-Debt Ratio
Avidity Biosciences, Inc cash flow-to-debt ratio. Avidity Biosciences, Inc (RNAM) has a Cash Flow-to-Debt Ratio of -0.63x as of December 2025, meaning its operating cash flow of $-169.77 Million could theoretically repay -1% of its total liabilities ($269.45 Million) in one year. See RNAM FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Avidity Biosciences, Inc (2018–2025)
Cash flow-to-debt ratio of Avidity Biosciences, Inc from 2018 to 2025. Historical debt coverage capacity for Avidity Biosciences, Inc across 8 annual periods. Check RNAM cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Avidity Biosciences, Inc Cash Flow-to-Debt Ratio by Year (2018–2025)
Avidity Biosciences, Inc cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Avidity Biosciences, Inc. For the full cash flow conversion analysis, see cash flow conversion of Avidity Biosciences, Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.41x | $-650.44 Million | $269.45 Million | ▼ -11.5% |
| 2024 | -2.17x | $-300.87 Million | $138.94 Million | ▼ -132.4% |
| 2023 | -0.93x | $-119.06 Million | $127.79 Million | ▲ +58.5% |
| 2022 | -2.24x | $-136.27 Million | $60.73 Million | ▼ -9.2% |
| 2021 | -2.05x | $-94.81 Million | $46.15 Million | ▼ -53.2% |
| 2020 | -1.34x | $-37.12 Million | $27.68 Million | ▼ -8839.9% |
| 2019 | 0.02x | $2.49 Million | $162.26 Million | ▲ +107.2% |
| 2018 | -0.21x | $-9.65 Million | $45.11 Million | — |